Oxybate sodium for parkinsonism.
D000284:Administration, Oral; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D006801:Humans; D006885:Hydroxybutyrates / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D010300:Parkinson Disease / Q000188:drug therapy*
D006885:Hydroxybutyrates; D004295:Dihydroxyphenylalanine